ImmunogenX makes key additions to its Scientific Advisory Board

Esteeemed scientific and business leaders bring strong assets

ImmunogenX™ is privileged to announce the addition of Prof. Jack Henion and Prof. David M Lubman to its Scientific Advisory Board.

Dr. Henion is an internationally recognized leader in the field of MS and LC/MS. He has published more than 200 peer-reviewed papers. In addition to his founding of Advion, one of the largest and most respected LC/MS contract laboratories in the world and a leader in chip-based nanoelectrospray mass spectrometry, Dr. Henion managed a major research laboratory at Cornell University, where he served as a professor of toxicology for more than 24 years and is now Emeritus Professor of Analytical Toxicology. He is the recipient of many honors and awards.

Professor Lubman is currently the Maude T. Lane Professor of Surgical Immunology and Professor of Surgery at the University of Michigan Medical Center, a Professor of Chemistry and Professor of Pathology. His present research interests involve developing new proteomic methods for searching for protein markers of cancer. These include 2-D liquid mapping of tumor cells and serum and also the development of protein microarray technology. Various collaborations with clinical researchers include studies in prostate, ovarian, pancreatic, colon and breast cancer.

Dr. Jennifer Sealey-Voyksner, CTO remarks “Prof. Henion is a luminary in the field of mass spectrometry and has been a treasured mentor for most of my professional career. We are ecstatic to have his expertise and commitment on board.” Dr. Jack A. Syage, CEO says “Prof. Lubman has had a long distinguished and highly creative career in medical applications in mass spectrometry. I have had the privilege to have worked with him for nearly three decades and applaud his service on the SAB of my previous company Syagen Technology up until its acquisition by the multinational aerospace company Safran.”

About ImmunogenX

“ImmunogenX” (a subsidiary of Immunogenics LLC) was founded in 2013 and is supported by a team of world-renowned clinicians, scientists and advisors. ImmunogenX is developing new advanced diagnostic screening methods to help individuals with suspected gluten sensitivities and/or diagnosed with celiac disease. For disease management we are extending and commercializing a successful clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment. This is a unique capability for which there are no other effective diagnostics. For food safety we are pioneering advanced methods to identify new physiologically relevant gluten peptide sequences in wheat, barley, and rye grain to greatly improve on the capability to screen for the full range of gluten proteins in food products.

www.ImmunogenX.com

For further information please contact

Jack A. Syage, PhD
CEO
714 357-0631
jsyage@immunogenx.com

“ImmunogenX™”, “Immunogenics™”, “CypCel™”, and “Allergenomics™” are trademarks of Immunogenics LLC